A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants

Novo Nordisk is developing a new study medicine, Etavopivat, to treat individuals with sickle cell disease (SCD). The purpose of the study is to determine the effect of Etavopivat on the electrical activity of the heart in healthy participants. The study comprises two parts: Part A and Part B. Part A investigates the safety of a high dose of Etavopivat. In this phase, participants will receive either a single dose of Etavopivat or a placebo. Which treatment the participant gets is decided by chance. In Part B, participants will get four different treatments on four different occasions: Etavopivat in 2 different doses (the new medicine that cannot be prescribed), a dummy medicine (placebo), and an already approved medicine (moxifloxacin). The order of the 4 study medicines is decided by chance. There will be a break of 7 days between each treatment. For Part A, the study duration will be from 10 to 36 days, and for Part B, the study duration will be from 27 to 53 days.

NCT Number	NCT07023029
Lead Sponsor	Novo Nordisk A/S
Conditions	Healthy Volunteers, Sickle Cell Disease, Thalassemia
Enrollment	33 participants
Start Date	2025-06-09
Primary Completion	2025-09-12 (estimated)
Study Completion	2025-09-22 (estimated)
Updated on ClinicalTrials.gov	2026-01-02